Drug Profile

DNL 921

Alternative Names: ATV Amyloid Beta - Denali Therapeutics; ATV-Amyloid-β - Denali Therapeutics; ATV-Aβ - Denali Therapeutics; DNL-921

Latest Information Update: 17 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Denali Therapeutics Inc
Class Antibodies; Antidementias
Mechanism of Action Amyloid beta-peptide inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Alzheimer's disease

Most Recent Events

07 Aug 2026 Phase-I clinical trials in Alzheimer's disease in United Kingdom (Parenteral) (NCT07758595)
10 Jul 2026 Denali Therapeutics files an clinical trial application with the for Alzheimer's disease prior to July 2026
10 Jul 2026 Pharmacodynamics data from a preclinical study in Alzheimer's disease released by Denali Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com